EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Factors Affecting the Safety and Effectiveness of Venom Immunotherapy

L Arzt-Gradwohl, S A Herzog, W Aberer, T Alfaya Arias, D Antolín-Amérigo, P Bonadonna, E Boni, A Bożek, M Chełmińska, B Ebner, N Frelih, R Gawlik und 27 weitere

Journal of Investigational Allergy and Clinical Immunology · 17.02.2025 · 35 (1) · 40-49

DOI: 10.18176/jiaci.0967 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Investigational Allergy and Clinical Immunology, online erschienen am 18.02.2025. Verfasst von L Arzt-Gradwohl und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Hypersensitivity. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety profile of venom immunotherapy (VIT) is a relevant issue, and considerable differences have been reported in the safety and efficacy of this treatment modality. The primary aim of this study was to evaluate the safety of angiotensin-converting enzyme inhibitors and ß-blockers during VIT. In a second analysis, we evaluated data on premedication and venom preparations and their association with systemic adverse events (AEs) during the up-dosing phase and the first year of the maintenance phase, as well as the outcome of field stings and sting challenges.

Methods

Ours was an open, prospective, observational, multicenter study that recruited 1425 patients, of whom 1342 underwent VIT.

Results

Premedication with oral antihistamines was taken by 52.1% of patients during up-dosing and 19.7% of patients during the maintenance phase. Antihistamines had no effect on the frequency of systemic AEs (P=.11), although large local reactions (LLRs) were less frequent (OR, 0.74; 95%CI, 0.58-0.96; P=.02). Aqueous preparations were preferred for up-dosing (73.0%), and depot preparations were used for the maintenance phase (64.5%). The type of venom preparation had no influence on the frequency of systemic AEs or on the effectiveness of VIT (P=.26 and P=.80, respectively), while LLRs were less frequent with depot preparations (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicHypersensitivityHumansMaleFemaleMiddle AgedAdultProspective StudiesAgedAnimalsAngiotensin-Converting Enzyme InhibitorsTreatment OutcomeHistamine AntagonistsAdrenergic beta-AntagonistsYoung AdultAdolescent

Stichwörter der Autor:innen

AnaphylaxisBee venomEffectivenessPremedicationSystemic adverse eventsVenom immunotherapyVenom preparationVespid venom

Substanzen

Angiotensin-Converting Enzyme InhibitorsHistamine AntagonistsAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria.
  • Allergy Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Príncipe de Asturias, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Madrid, Spain.
  • Servicio de Alergia, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.
  • Allergy Unit, Verona General Hospital, Verona, Italy.

Zitieren

APA

Arzt-Gradwohl, L., Herzog, S. A., Aberer, W., Alfaya Arias, T., Antolín-Amérigo, D., Bonadonna, P., Boni, E., Bożek, A., Chełmińska, M., Ebner, B., Frelih, N., Gawlik, R., Gelincik, A., Hawranek, T., Hoetzenecker, W., Jiménez Blanco, A., Kita, K., Kendirlinan, R., Košnik, M., …, & Sturm, G. J. (2025). Factors Affecting the Safety and Effectiveness of Venom Immunotherapy. Journal of Investigational Allergy and Clinical Immunology, 35(1), 40-49. https://doi.org/10.18176/jiaci.0967

Vancouver

Arzt-Gradwohl L, Herzog SA, Aberer W, Alfaya Arias T, Antolín-Amérigo D, Bonadonna P, et al. Factors Affecting the Safety and Effectiveness of Venom Immunotherapy. Journal of Investigational Allergy and Clinical Immunology. 2025;35(1):40-49. doi:10.18176/jiaci.0967

BibTeX
@article{ArztGradwohl2025,
  author = {Arzt-Gradwohl, L and Herzog, S A and Aberer, W and Alfaya Arias, T and Antolín-Amérigo, D and Bonadonna, P and Boni, E and Bożek, A and Chełmińska, M and Ebner, B and Frelih, N and Gawlik, R and Gelincik, A and Hawranek, T and Hoetzenecker, W and Jiménez Blanco, A and Kita, K and Kendirlinan, R and Košnik, M and Laipold, K and Lang, R and Marchi, F and Mauro, M and Nittner-Marszalska, M and Poziomkowska-Gęsicka, I and Pravettoni, V and Preziosi, D and Quercia, O and Reider, N and Rosiek-Biegus, M and Ruiz-Leon, B and Schrautzer, C and Serrano, P and Sin, A and Sin, B A and Stoevesandt, J and Trautmann, A and Vachová, M and Sturm, G J},
  title = {Factors Affecting the Safety and Effectiveness of Venom Immunotherapy},
  journal = {Journal of Investigational Allergy and Clinical Immunology},
  year = {2025},
  volume = {35},
  number = {1},
  pages = {40--49},
  doi = {10.18176/jiaci.0967}
}
Kostenlos starten →